# Peptide tested on mini retinas may protect the sight of people with diabetes

In retinas grown in the lab from patients' cells, the peptide Ac2-26 stopped the death of neurons exposed to excess sugar. The study, by Brazil's Unifesp and Unesp with the University of Colorado, opens the way to preventing diabetic retinopathy before the damage becomes permanent.

- Section: Health
- Published: November 17, 2026
- Address: https://ceoone.com.br/en/article/peptide-tested-on-mini-retinas-may-protect-the-sight-of-people-with-diabetes
- Em português: https://ceoone.com.br/artigo/peptideo-testado-em-minirretinas-pode-proteger-a-visao-de-quem-tem-diabetes.md

![Fundus exam: the orange retina, with the pale optic disc and branching blood vessels, dotted with small yellowish spots and red blotches of diabetic retinopathy](https://pub-b80e49b2737940b3ab5d3f20d0578192.r2.dev/artigos/peptideo-testado-em-minirretinas-pode-proteger-a-visao-de-quem-tem-diabetes-foto.webp)

Photo: Hao et al./Wikimedia Commons (CC BY 4.0)

## Key points

- In mini retinas made from patients' cells, the peptide Ac2-26 stopped the death of neurons exposed to excess sugar.
- The study is by Unifesp and Unesp, with the University of Colorado and funding from Fapesp.
- Diabetic retinopathy affects more than 22% of people with diabetes, and current treatments often come too late to protect the neurons.

A molecule the body makes on its own may help protect eyesight against the damage caused by too much sugar in the blood. In laboratory tests, the peptide Ac2-26 prevented the death of retinal neurons exposed to high glucose levels, according to a study published in the journal Biomedicine & Pharmacotherapy. The result opens the way to new strategies for preventing diabetic retinopathy.

The complication affects more than 22% of people with diabetes worldwide. It appears when high blood sugar causes inflammation and damages neurons and blood vessels in the retina, and it can lead to permanent loss of vision.

## Mini retinas made from patients' cells

The research, funded by Fapesp, the São Paulo Research Foundation, brought together scientists from the Federal University of São Paulo (Unifesp) and São Paulo State University (Unesp), in partnership with the University of Colorado Anschutz, in the United States. The group tested Ac2-26, which is part of an anti-inflammatory protein called annexin A1, in models that mimic the human eye: cultures of isolated retinal cells and three-dimensional structures that work as "mini retinas", known as organoids. Both were derived from patients' stem cells.

![Cross-section of a retinal organoid under the microscope, dome-shaped, with cell nuclei in blue and a rim of photoreceptor cells in green on a black background](https://pub-b80e49b2737940b3ab5d3f20d0578192.r2.dev/artigos/peptideo-testado-em-minirretinas-pode-proteger-a-visao-de-quem-tem-diabetes-organoide.webp)

A retinal organoid grown in the lab from a patient's cells at the US National Eye Institute (illustrative image, not from the Brazilian study). Photo: National Eye Institute/NIH (public domain)

In the experiments, the peptide acted on several fronts. It reduced inflammation, contained oxidative stress and protected the function of mitochondria, the structures that produce energy for cells. Together, these actions prevented the death of neurons exposed to high glucose.

"We were able to show a protective effect on the retina and a potential new strategy for preventing diabetic retinopathy," says Cristiane Gil, head of the Department of Morphology and Genetics at the Escola Paulista de Medicina (EPM-Unifesp) and a co-author of the paper.

## One step after another

In an earlier study published in Investigative Ophthalmology & Visual Science, Gil's group had already shown the role of annexin A1 in regulating inflammation and changes in blood vessels and in glial cells, which nourish and support neurons. What was missing was testing the peptide in organoids that reproduce the disease.

As retinopathy progresses, the toxic environment created by oxidative stress and inflammation leads to the early death of retinal neurons. That is where Ac2-26 comes in.

## Before the damage, not after

"The peptide inhibits the pathways that signal cell death, preventing retinal neurons from dying, something current treatments for diabetic retinopathy cannot do," explains Rafael André da Silva, a researcher at the University of Colorado. Today, the available therapies act at a later stage of the disease, neovascularization, when new blood vessels form in the retina. "And they often come too late to protect the neuronal cells."

The results come from laboratory tests. The researchers' hope is that, in the future, protection can begin before sight is lost.

## Sources and editorial notes

- Based on the report "Ação preventiva na perda de visão por diabetes" (Preventive action against vision loss from diabetes), by Maria Fernanda Ziegler of Agência Fapesp, published in the Para Fechar section of O Estado de S. Paulo on November 17, 2026.

CEO ONE · https://ceoone.com.br

